Base de dados : MEDLINE
Pesquisa : C19.874.397.685 [Categoria DeCS]
Referências encontradas : 2721 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 273 ir para página                         

  1 / 2721 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953662
[Au] Autor:Abramavicius S; Velickiene D; Kadusevicius E
[Ad] Endereço:aInstitute of Physiology and Pharmacology, Lithuanian University of Health Sciences bInstitute of Endocrinology, Lithuanian University of Health Sciences cInstitute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
[Ti] Título:Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report.
[So] Source:Medicine (Baltimore);96(39):e8159, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS: A 74-year-old woman presented with spontaneous retro-bulbar pain, eyelid swelling and inconstant diplopia. DIAGNOSES: Thyrotoxicosis and severe GO with suspected optic nerve damage and drug induced liver injury (DILI). INTERVENTIONS: Intravenous methylprednisolone pulse therapy was administered to treat GO and methimazole was continued for thyrotoxicosis. Dose of methimazole was reduced after exclusion of concurrent infection and active liver disease. OUTCOMES: The GO symptoms (eyelid swelling, sight loss, proptosis, retro-bulbar pain, diplopia) markedly decreased after the treatment course. Liver transaminases spontaneously returned to normal ranges and remained normal during the next 12 months until the Graves' disease until the treatment was completed. LESSONS: 1. The interaction of methimazole and methylprednisolone may result in DILI. 2. In a patient without concomitant liver diseases MP can be continued if the methimazole dose is reduced if no other treatment options are available.
[Mh] Termos MeSH primário: Doença Hepática Induzida por Substâncias e Drogas
Oftalmopatia de Graves
Metimazol
Metilprednisolona
Doenças do Nervo Óptico
Tireotoxicose
[Mh] Termos MeSH secundário: Administração Intravenosa
Idoso
Antitireóideos/administração & dosagem
Antitireóideos/efeitos adversos
Doença Hepática Induzida por Substâncias e Drogas/diagnóstico
Doença Hepática Induzida por Substâncias e Drogas/fisiopatologia
Doença Hepática Induzida por Substâncias e Drogas/terapia
Relação Dose-Resposta a Droga
Feminino
Glucocorticoides/administração & dosagem
Glucocorticoides/efeitos adversos
Oftalmopatia de Graves/diagnóstico
Oftalmopatia de Graves/tratamento farmacológico
Oftalmopatia de Graves/fisiopatologia
Seres Humanos
Testes de Função Hepática
Conduta do Tratamento Medicamentoso
Metimazol/administração & dosagem
Metimazol/efeitos adversos
Metilprednisolona/administração & dosagem
Metilprednisolona/efeitos adversos
Doenças do Nervo Óptico/complicações
Doenças do Nervo Óptico/diagnóstico
Doenças do Nervo Óptico/fisiopatologia
Pulsoterapia/métodos
Avaliação de Sintomas/métodos
Tireotoxicose/complicações
Tireotoxicose/diagnóstico
Tireotoxicose/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antithyroid Agents); 0 (Glucocorticoids); 554Z48XN5E (Methimazole); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008159


  2 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28572231
[Au] Autor:Gilbert J
[Ad] Endereço:King's College Hospital, Denmark Hill, London jackiegilbert@nhs.net.
[Ti] Título:Thyrotoxicosis - investigation and management .
[So] Source:Clin Med (Lond);17(3):274-277, 2017 Jun.
[Is] ISSN:1473-4893
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Graves' disease (GD) and toxic nodular (TN) goitre account for most cases of thyrotoxicosis associated with hyperthyroidism. Hyperthyroidism is confirmed with measurement of a suppressed serum thyrotropin concentration (TSH) and elevated free thyroid hormones. The three therapeutic options are antithyroid drugs, radioactive iodine and surgery. Thionamides achieve long-term remission in 35% of cases. Many centres administer fixed doses of iodine-131; larger doses result in improved rates of cure at the cost of hypothyroidism. Surgery is usually considered for patients who have a large goitre, compressive symptoms or significant ophthalmopathy.
[Mh] Termos MeSH primário: Tireotoxicose
[Mh] Termos MeSH secundário: Antitireóideos/uso terapêutico
Bócio Nodular
Doença de Graves
Seres Humanos
Radioisótopos do Iodo/uso terapêutico
Tireotoxicose/diagnóstico
Tireotoxicose/fisiopatologia
Tireotoxicose/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antithyroid Agents); 0 (Iodine Radioisotopes)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE
[do] DOI:10.7861/clinmedicine.17-3-274


  3 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28569635
[Au] Autor:Morré WA; Panciera DL; Daniel GB; Refsal KR; Rick M; Arrington K
[Ti] Título:Thyrotoxicosis induced by excessive 3,5,3'-triiodothyronine in a dog.
[So] Source:J Am Vet Med Assoc;250(12):1427-1431, 2017 Jun 15.
[Is] ISSN:1943-569X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE DESCRIPTION A 7-year-old castrated male Havanese was evaluated at a veterinary teaching hospital because of a 12-week history of hyperactivity, aggression, and progressive weight loss despite a healthy appetite. CLINICAL FINDINGS Tachycardia was the only remarkable finding during physical examination. Serum 3,5,3'-triiodothyronine (T3) and free T3 concentrations were markedly increased, and thyroxine (T4), free T4, and thyroid-stimulating hormone concentrations were at or decreased from the respective reference ranges. Thyroid scintigraphy revealed suppressed uptake of sodium pertechnetate Tc 99m by the thyroid gland but no ectopic thyroid tissue, which was indicative of thyrotoxicosis induced by an exogenous source of T3. TREATMENT AND OUTCOME The dog was hospitalized for 24 hours, and its diet was changed, after which the clinical signs rapidly resolved and serum T3 and free T3 concentrations returned to within the respective reference ranges. This raised suspicion of an exogenous source of T3 in the dog's home environment. Analysis of the commercial beef-based canned food the dog was being fed revealed a high concentration of T3 (1.39 µg/g) and an iodine (82.44 µg/g) concentration that exceeded industry recommendations. No other source of T3 was identified in the dog's environment. CLINICAL RELEVANCE To our knowledge, this is the first report of clinical thyrotoxicosis in a dog induced by exogenous T3, although the source of exogenous T3 was not identified. This case highlights the importance of measuring serum T3 and thyroid-stimulating hormone concentrations in addition to T4 and free T4 concentrations when there is incongruity between clinical findings and thyroid function test results.
[Mh] Termos MeSH primário: Doenças do Cão/diagnóstico
Contaminação de Alimentos
Tireotoxicose/veterinária
Tiroxina/efeitos adversos
[Mh] Termos MeSH secundário: Ração Animal/análise
Animais
Diagnóstico Diferencial
Doenças do Cão/sangue
Cães
Masculino
Tireotoxicose/diagnóstico
Tireotoxicose/etiologia
Tiroxina/sangue
Tiroxina/química
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.2460/javma.250.12.1427


  4 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28424174
[Au] Autor:Benjamens S; Dullaart RPF; Sluiter WJ; Rienstra M; van Gelder IC; Links TP
[Ad] Endereço:Department of Internal MedicineDivision of Endocrinology.
[Ti] Título:The clinical value of regular thyroid function tests during amiodarone treatment.
[So] Source:Eur J Endocrinol;177(1):9-14, 2017 Jul.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Amiodarone is used for the maintenance of sinus rhythm in patients with arrhythmias, but thyroid dysfunction (amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH)) is a common adverse effect. As the onset of AIT and AIH may be unpredictable, the value of long-term regular monitoring of amiodarone treated patients for thyroid dysfunction is still uncertain. DESIGN: We retrospectively documented the frequency at which overt thyroid dysfunction was preceded by subclinical thyroid dysfunction. METHODS: We included 303 patients treated with amiodarone between 1984 and 2007. AIT was defined as a lowered TSH level with an elevated free thyroxine (FT4) and AIH was defined as an elevated TSH level with a decreased or subnormal FT4. Subclinical AIT was defined as a lowered TSH level with a normal FT4 and subclinical AIH as an elevated TSH level with a normal FT4. RESULTS: 200 men and 103 women, aged 62 ± 12.0 years, suffering from atrial (260) or ventricular (43) arrhythmias, were evaluated. During a median follow-up of 2.8 (1.0-25) years, 44 patients developed AIT and 33 AIH. In 42 (55%) patients who developed AIT/AIH, earlier thyroid function tests showed no subclinical AIT or subclinical AIH. In 35 (45%) patients, AIT/AIH was preceded by subclinical AIT or subclinical AIH (16/44 for AIT and 19/33 for AIH). CONCLUSIONS: In a considerable proportion of patients who developed AIT/AIH, earlier thyroid function tests showed no subclinical AIT/AIH. Less than half of the patients with a subclinical event subsequently developed overt AIT/AIH. This study provides data to reconsider the yield of regular testing of thyroid function to predict overt thyroid dysfunction in amiodarone treated patients.
[Mh] Termos MeSH primário: Amiodarona/efeitos adversos
Amiodarona/uso terapêutico
Antiarrítmicos/efeitos adversos
Antiarrítmicos/uso terapêutico
Testes de Função Tireóidea
[Mh] Termos MeSH secundário: Adulto
Idoso
Arritmias Cardíacas/complicações
Arritmias Cardíacas/tratamento farmacológico
Feminino
Seguimentos
Seres Humanos
Hipotireoidismo/induzido quimicamente
Hipotireoidismo/diagnóstico
Hipotireoidismo/epidemiologia
Masculino
Meia-Idade
Monitorização Fisiológica
Estudos Retrospectivos
Tireotoxicose/induzido quimicamente
Tireotoxicose/diagnóstico
Tireotoxicose/epidemiologia
Tireotropina/sangue
Tiroxina/sangue
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 9002-71-5 (Thyrotropin); N3RQ532IUT (Amiodarone); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0018


  5 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28398380
[Au] Autor:Bogazzi F; Tomisti L; Di Bello V; Martino E
[Ad] Endereço:Unità di Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi, Pisa.
[Ti] Título:[Amiodarone-induced thyrotoxicosis].
[Ti] Título:Tireotossicosi indotta da amiodarone..
[So] Source:G Ital Cardiol (Rome);18(3):219-229, 2017 Mar.
[Is] ISSN:1827-6806
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:Amiodarone-induced thyroid dysfunction occurs in about 15-20% of patients under amiodarone therapy. Amiodarone-induced hypothyroidism (AIH) can develop in patients with an apparently normal thyroid gland or in those with an underlying chronic autoimmune thyroiditis. On a clinical ground, AIH is not challenging and can be easily treated with L-thyroxine therapy. Amiodarone-induced thyrotoxicosis (AIT) can occur in patients with (AIT 1) or without (AIT 2) an underlying thyroid disease. AIT 1 is a true iodine-induced hyperthyroidism occurring in patients with an underlying thyroid autonomy while AIT 2 is a drug-induced destructive thyroiditis. According to the different pathogenetic mechanism, AIT 2 is treated with glucocorticoids while AIT 1 usually responds to thionamides. Thyroidectomy should be considered when AIT represents an imminent risk for cardiac conditions, when patients require a prompt resolution of thyrotoxicosis or when they do not respond to the medical therapy. An effective collaboration between cardiologists and endocrinologists is crucial in each part of the management of AIT patients, including the evaluation of cardiological conditions with regard to thyroid hormone excess and whether, or not, it is necessary to continue amiodarone therapy.
[Mh] Termos MeSH primário: Amiodarona/efeitos adversos
Antiarrítmicos/efeitos adversos
Tireotoxicose/etiologia
[Mh] Termos MeSH secundário: Seres Humanos
Hipotireoidismo
Glândula Tireoide/efeitos dos fármacos
Glândula Tireoide/fisiopatologia
Tireotoxicose/diagnóstico
Tireotoxicose/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1714/2674.27399


  6 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368068
[Au] Autor:Kempker K; Güssow A; Cook AM; Rick M; Neiger R
[Ad] Endereço:Karsten Kempker, Klinik für Kleintiere - Innere Medizin, Justus-Liebig-Universität Gießen, Frankfurter Straße 126, 35392 Gießen, E-Mail: Karsten.Kempker@vetmed.uni-giessen.de.
[Ti] Título:[Alimentary thyrotoxcicosis in two dogs].
[Ti] Título:Alimentäre Thyreotoxikose bei zwei Hunden..
[So] Source:Tierarztl Prax Ausg K Kleintiere Heimtiere;45(3):193-198, 2017 Jun 20.
[Is] ISSN:1434-1239
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Two dogs with increased thyroxin concentrations compatible with hyperthyroidism were referred for further examinations. One dog displayed clinical signs of hyperthyroidism. Based on history, clinical examination, laboratory evaluation and scintigraphy an alimentary thyrotoxicosis was identified. It was caused by feeding a BARF diet containing thyroidal tissue in one dog and by conventional dog food in the other patient. After changing the diet the clinical signs resolved in the affected dog. A control examination revealed thyroxin concentrations within the reference range in both dogs.
[Mh] Termos MeSH primário: Doenças do Cão/diagnóstico
Tireotoxicose/veterinária
[Mh] Termos MeSH secundário: Ração Animal
Animais
Doenças do Cão/sangue
Doenças do Cão/dietoterapia
Doenças do Cão/fisiopatologia
Cães
Tireotoxicose/diagnóstico
Tireotoxicose/dietoterapia
Tireotoxicose/fisiopatologia
Tiroxina/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.15654/TPK-160554


  7 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28274950
[Au] Autor:Albuquerque EV; Scalco RC; Jorge AA
[Ad] Endereço:Unidade de Endocrinologia GenéticaLaboratório de Endocrinologia Celular e Molecular (LIM/25), Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature.
[So] Source:Eur J Endocrinol;176(6):R339-R353, 2017 Jun.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tall stature is defined as a height of more than 2 standard deviations (s.d.) above average for same sex and age. Tall individuals are usually referred to endocrinologists so that hormonal disorders leading to abnormal growth are excluded. However, the majority of these patients have familial tall stature or constitutional advance of growth (generally associated with obesity), both of which are diagnoses of exclusion. It is necessary to have familiarity with a large number of rarer overgrowth syndromes, especially because some of them may have severe complications such as aortic aneurysm, thromboembolism and tumor predisposition and demand-specific follow-up approaches. Additionally, endocrine disorders associated with tall stature have specific treatments and for this reason their recognition is mandatory. With this review, we intend to provide an up-to-date summary of the genetic conditions associated with overgrowth to emphasize a practical diagnostic approach of patients with tall stature and to discuss the limitations of current growth interruption treatment options.
[Mh] Termos MeSH primário: Estatura
Transtornos do Crescimento/diagnóstico
[Mh] Termos MeSH secundário: Acromegalia/diagnóstico
Acromegalia/metabolismo
Acromegalia/terapia
Síndrome de Beckwith-Wiedemann/complicações
Síndrome de Beckwith-Wiedemann/diagnóstico
Cromossomos Humanos X/genética
Gerenciamento Clínico
Síndrome do Cromossomo X Frágil/complicações
Transtornos do Crescimento/etiologia
Transtornos do Crescimento/genética
Transtornos do Crescimento/terapia
Lâmina de Crescimento/cirurgia
Homocistinúria/complicações
Homocistinúria/diagnóstico
Homocistinúria/genética
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Síndrome de Klinefelter/diagnóstico
Síndrome de Klinefelter/genética
Síndrome de Marfan/diagnóstico
Síndrome de Marfan/genética
Obesidade/complicações
Aberrações dos Cromossomos Sexuais
Transtornos do Cromossomo Sexual no Desenvolvimento Sexual/diagnóstico
Transtornos do Cromossomo Sexual no Desenvolvimento Sexual/genética
Síndrome de Sotos/complicações
Síndrome de Sotos/diagnóstico
Síndrome de Sotos/genética
Tireotoxicose/complicações
Trissomia/diagnóstico
Trissomia/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-16-1054


  8 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28274949
[Au] Autor:Carlé A; Andersen SL; Boelaert K; Laurberg P
[Ad] Endereço:Department of Endocrinology carle@dadlnet.dk.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Subclinical thyrotoxicosis: prevalence, causes and choice of therapy.
[So] Source:Eur J Endocrinol;176(6):R325-R337, 2017 Jun.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Subclinical thyrotoxicosis is a condition affecting up to 10% of the population in some studies. We have reviewed literature and identified studies describing prevalences, causes and outcomes of this condition. Treatment should be considered in all subjects if this biochemical abnormality is persistent, especially in case of symptoms of thyrotoxicosis or in the presence of any complication. In particular, treatment should be offered in those subclinically thyrotoxic patients with a sustained serum TSH below 0.1 U/L. However it is important to recognise that there are no large controlled intervention studies in the field and thus there is no high quality evidence to guide treatment recommendations. In particular, there is no evidence for therapy and there is weak evidence of harm from thyrotoxicosis if serum TSH is in the 0.1-0.4 IU/L range. In this review, we describe the different causes of subclinical thyrotoxicosis, and how treatment should be tailored to the specific cause. We advocate radioactive iodine treatment to be the first-line treatment in majority of patients suffering from subclinical thyrotoxicosis due to multinodular toxic goitre and solitary toxic adenoma, but we do generally not recommend it as the first-line treatment in patients suffering from subclinical Graves' hyperthyroidism. Such patients may benefit mostly from antithyroid drug therapy. Subclinical thyrotoxicosis in early pregnancy should in general be observed, not treated. Moreover, we advocate a general restriction of therapy in cases where no specific cause for the presumed thyroid hyperactivity has been proven.
[Mh] Termos MeSH primário: Doenças Assintomáticas/terapia
Medicina de Precisão
Glândula Tireoide/fisiopatologia
Tireotoxicose/terapia
[Mh] Termos MeSH secundário: Doenças Assintomáticas/epidemiologia
Comorbidade
Seres Humanos
Guias de Prática Clínica como Assunto
Prevalência
Tireotoxicose/epidemiologia
Tireotoxicose/etiologia
Tireotoxicose/fisiopatologia
Conduta Expectante
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-16-0276


  9 / 2721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28199740
[Au] Autor:Lin TY; Shekar AO; Li N; Yeh MW; Saab S; Wilson M; Leung AM
[Ad] Endereço:UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
[Ti] Título:Incidence of abnormal liver biochemical tests in hyperthyroidism.
[So] Source:Clin Endocrinol (Oxf);86(5):755-759, 2017 May.
[Is] ISSN:1365-2265
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Abnormal serum liver function tests are common in patients with untreated thyrotoxicosis, even prior to the initiation of antithyroidal medications that may worsen the severity of the abnormal serum liver biochemistries. There is a wide range of the incidence of these abnormalities in the published literature. The aim of this study was to assess the risks factors and threshold of thyrotoxicosis severity for developing an abnormal liver biochemical test upon the diagnosis of new thyrotoxicosis. DESIGN: Single-institution retrospective cohort study. PATIENTS: Patients of ≥18 years old receiving medical care at a large, academic, urban US medical centre between 2002-2016. MEASUREMENTS: Inclusion criteria were a serum thyroid stimulating hormone (TSH) concentration of <0·3 mIU/l or ICD-9 code for thyrotoxicosis, with thyrotoxicosis confirmed by either a concurrent elevated serum triiodothyronine (T3) or thyroxine (T4) concentration ([total or free] within 3 months), and an available liver biochemical test(s) within 6 months of thyrotoxicosis. The biochemical liver tests assessed were serum aspartate transaminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), gamma-glutamyltransferase (GGT), total bilirubin, and conjugated bilirubin concentrations. RESULTS: In this cohort of 1514 subjects, the overall incidence of any biochemical liver test abnormality within 6 months of thyrotoxicosis was 39%. An initial serum TSH concentration <0·02 mIU/l, male gender, and African-American race were significant predictors of an abnormal serum liver biochemical test within 6 months of the diagnosis of new-onset untreated thyrotoxicosis. CONCLUSIONS: This study identifies risk factors for patients who develop an abnormal serum liver biochemical test result within 6 months of a diagnosis of untreated thyrotoxicosis.
[Mh] Termos MeSH primário: Hipertireoidismo/sangue
Hepatopatias/sangue
Tireotoxicose/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Incidência
Testes de Função Hepática
Masculino
Meia-Idade
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE
[do] DOI:10.1111/cen.13312


  10 / 2721 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28183855
[Au] Autor:Seymour M; Morton A
[Ad] Endereço:Mater Misericordiae Health Services Brisbane Ltd, Queensland Diabetes and Endocrine Centre, South Brisbane, Queensland, Australia.
[Ti] Título:Unilateral facial swelling in a thyrotoxic patient.
[So] Source:BMJ;356:j534, 2017 Feb 09.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Agranulocitose/induzido quimicamente
Edema/etiologia
Face
Parotidite/etiologia
Tireotoxicose/diagnóstico por imagem
[Mh] Termos MeSH secundário: Idoso
Agranulocitose/diagnóstico por imagem
Agranulocitose/tratamento farmacológico
Amiodarona/efeitos adversos
Amiodarona/uso terapêutico
Antiarrítmicos/efeitos adversos
Antiarrítmicos/uso terapêutico
Diagnóstico Diferencial
Febre/etiologia
Seres Humanos
Masculino
Neutropenia/induzido quimicamente
Neutropenia/tratamento farmacológico
Parotidite/diagnóstico por imagem
Parotidite/tratamento farmacológico
Tireotoxicose/induzido quimicamente
Tireotoxicose/tratamento farmacológico
Tireotoxicose/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170331
[Lr] Data última revisão:
170331
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j534



página 1 de 273 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde